[Funding alert] London-based Samphire Neuroscience Secures €2.1 Million in Pre-Seed Funding

Prominent angel investors like Dr. Pamela Walker of Thena Capital, Rowena Ironside of Women on Boards UK, Russell Buckley, the creator of Kindred Capital, and the former chairman of Touch Surgery all participated in the round.

Read also - Eindhoven-based Scinvivo Raises €4.7 Million in Funding

Up to 91% of women who are of reproductive age experience dysmenorrhea, or cramping during menstruation, and over 90% of them will at some point in their lives experience mild to severe premenstrual symptoms.

A monthly struggle that many women are familiar with is severe menstrual cramps, in addition to the emotional and physical symptoms that occur during the luteal phase (the five to ten days before to your period). According to studies, these symptoms have a detrimental effect on people's quality of life and cost the UK economy around £118 billion yearly due to nearly nine days of lost productivity annually.

Read also - Darmstadt-based Threedy Raises €9.6 Million in Series A Round Funding

But the real impact of menstruation discomfort and PMS goes beyond statistics. A monthly recurrence starts an unending cycle of suffering. Despite their good intentions, the majority of medical interventions have drawbacks of their own and require substantial sacrifices.

For instance, a hysterectomy is officially advised as a treatment for severe menstruation problems; however, apart from curing the symptoms, the operation also renders the patient incapable of getting pregnant in the future.

Read also - Copenhagen-based Spektr Secures €5 Million in Funding

Samphire Neuroscience was co-founded by Oxford-educated barrister Alex Cook and Harvard-educated neuroscientist Emilė Radytė because they believed that women should have more treatment alternatives.

Their vast combined experience in the lab, the clinic, the field of public health and policy, and the technology industry has resulted in Samphire. They are determined to provide solutions that are efficient, secure, and especially suited to the needs of women without making significant concessions through research, creativity, and a commitment to comprehending the nuances of the female brain.

Read also - Tallinn-based Cognitiwe Secures €1Million in Funding

Emilė Radytė, CEO and Co-Founder of Samphire Neuroscience, said: “Women’s health has been notoriously under-researched and underfunded for decades. As a result, women have been expected to compromise when it comes to taking care of their minds and bodies. What we’re doing is approaching things differently – with the brain as the nexus of health. A number of scientific studies have highlighted the potential of brain-based therapies. Mental and physical well-being are essential components of a complex system governed by the brain, and unlocking that system’s capabilities will lead to breakthroughs beyond our current understanding, and Samphire is going to help forge that path.”

Duncan Turner, General Partner at SOSV, commented: “I have spent my career investing in mental health solutions, and was struck by how unique Samphire’s approach is. It not only pays attention to – and gives a solution for – challenges that are so common yet overlooked, but also aims to support women across their lives, so they could thrive.”

About Samphire Neuroscience

Samphire Neuroscience was founded with the goal of enabling women worldwide to have wearable technology that has been scientifically proven for their health needs without compromising on design, technology, or lifestyle.

Read also - French-based AZmed Secures €15Milion in Series A Round Funding

Based on over thirty years of research and clinical expertise, we are creating the Samphire Headband, a wearable neurotechnology that solves a variety of issues associated to the menstrual cycle.